<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003042</url>
  </required_header>
  <id_info>
    <org_study_id>96139</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-96139</secondary_id>
    <secondary_id>NCI-G97-1288</secondary_id>
    <secondary_id>CDR0000065672</secondary_id>
    <nct_id>NCT00003042</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer</brief_title>
  <official_title>Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well chemotherapy and stem cell transplantation&#xD;
      work in treating patients with stage IIIB breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effectiveness of neoadjuvant dose intensive sequential chemotherapy,&#xD;
           followed by surgical resection, adjuvant therapy, and tandem high dose chemotherapy and&#xD;
           stem cell rescue in patients with inflammatory stage IIIB breast cancer.&#xD;
&#xD;
        -  Determine the clinical and pathological remission rate (complete, partial, and overall)&#xD;
           following neoadjuvant dose dependent sequential chemotherapy in patients with&#xD;
           inflammatory stage IIIB breast cancer.&#xD;
&#xD;
        -  Determine the relapse and survival rate of these patients with the above therapy.&#xD;
&#xD;
        -  Determine the potential correlations between inflammatory features and hereditary&#xD;
           background.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to those who have had no more than 1 cycle of&#xD;
      neoadjuvant chemotherapy (stratum 1) and those who have had more than 1 cycle of neoadjuvant&#xD;
      chemotherapy and/or modified radical mastectomy (stratum 2).&#xD;
&#xD;
      Patients in stratum 1 receive doxorubicin IV over 96 hours on days 1-4, 15-19, and 29-32.&#xD;
      Paclitaxel is infused over 96 hours on days 43-47 and 57-60. Filgrastim (G-CSF) is&#xD;
      administered on days 5-10, 20-25, 33-38, 48-55, and 61-68, and beyond if the granulocyte&#xD;
      count is less than 1000/mm^3. A modified radical mastectomy is performed between days 70 and&#xD;
      80. All stratum 1 and stratum 2 patients then receive paclitaxel IV for 96 hours on days&#xD;
      100-104, and cyclophosphamide IV on day 121. Filgrastim is administered at one dose on days&#xD;
      105-110 and days 122-127 and at a higher dose on days 110-116 and days 128-135. Stem cells&#xD;
      are harvested from the patient on days 113-116 and days 132-135.&#xD;
&#xD;
      High-dose chemotherapy is then administered to all patients in the study. Course 1 starts&#xD;
      with doxorubicin IV on days -7 to -3. Paclitaxel IV is administered for 24 hours on day -2.&#xD;
      Filgrastim is administered by IV on day -1 and continued until the granulocyte count is&#xD;
      greater than 1000/mm^3 for 3 days. Peripheral stem cells are reinfused on day 0. Course 2&#xD;
      starts 4-6 weeks after the start of course 1 with melphalan and cisplatin being infused on&#xD;
      day -11. Filgrastim is administered IV on days -10 to -6. Melphalan and cisplatin are&#xD;
      administered again on day -4. Stem cells are infused on day -3 and on day 0. Filgrastim is&#xD;
      then administered until the granulocyte count is at least 1000/mm^3 for 3 days.&#xD;
&#xD;
      Radiation therapy is started 4-7 weeks after the beginning of course 2. Tamoxifen is started&#xD;
      within 2 weeks of discharge following course 2 in patients with hormone receptor positive&#xD;
      tumors.&#xD;
&#xD;
      Patients are followed every 3 months for two years and then annually for the next three&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 60 patients will be accrued, at a rate of about 15 per year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 1997</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Three-year Relapse-free Survival</measure>
    <time_frame>From date of mastectomy until date of relapse or death from any cause, 3 years post mastectomy.</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier. Relapse defined as appearance of any new lesions during or after protocol treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Five-year Overall Survival</measure>
    <time_frame>From date of mastectomy until date of death, 5 years post mastectomy.</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier. Endpoint is defined as death due to any cause.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesna</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>1 cycle of neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>More than 1 cycle of neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven stage IIIB breast cancer with dermal/epidermal invasion or&#xD;
             clinical features of inflammation, erythema, pain or hypersensitivity, edema, or&#xD;
             thickening of the skin&#xD;
&#xD;
          -  Diagnosis within the past 6 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  60 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT or SGPT no greater than 1.5 times the upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.2 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 80 mL/min&#xD;
&#xD;
          -  No history of hemorrhagic cystitis&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Left ventricular fraction at least 55% on MUGA scan&#xD;
&#xD;
          -  No previous valvular heart disease or arrhythmia&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1 at least 60% predicted&#xD;
&#xD;
          -  Room air pO_2 greater than 85 mmHg&#xD;
&#xD;
          -  Room air pCO_2 no greater than 43 mmHg&#xD;
&#xD;
          -  DLCO at least 60% of the lower limit of predicted value&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of malignant disease in the past 5 years, except for squamous or basal cell&#xD;
             skin cancer and stage I or in situ cervical cancer&#xD;
&#xD;
          -  No organic CNS dysfunction&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No known and potentially disabling psychosocial history&#xD;
&#xD;
          -  Not positive for hepatitis B or HIV&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Stratum 1:&#xD;
&#xD;
               -  No more than one cycle of chemotherapy&#xD;
&#xD;
          -  Stratum 2:&#xD;
&#xD;
               -  No greater than 225 mg/m^2 doxorubicin and no greater than 250 mg/m^2 paclitaxel&#xD;
                  during previous chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiation to the left chest wall&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Modified radical mastectomy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Somlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>March 12, 2021</results_first_submitted>
  <results_first_submitted_qc>March 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>February 17, 2022</last_update_submitted>
  <last_update_submitted_qc>February 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT00003042/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neoadjuvant Chemo Followed by Surgery &amp; High-dose Chemo With PSC Rescue</title>
          <description>Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
cyclophosphamide&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
conventional surgery&#xD;
peripheral blood stem cell transplantation</description>
        </group>
        <group group_id="P2">
          <title>High-dose Chemo With Rescue</title>
          <description>Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
peripheral blood stem cell transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neoadjuvant Chemo Followed by Surgery &amp; High-dose Chemo With PSC Rescue</title>
          <description>Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
cyclophosphamide&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
conventional surgery&#xD;
peripheral blood stem cell transplantation</description>
        </group>
        <group group_id="B2">
          <title>High-dose Chemo With Rescue</title>
          <description>Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
peripheral blood stem cell transplantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="30" upper_limit="61"/>
                    <measurement group_id="B2" value="50" lower_limit="34" upper_limit="61"/>
                    <measurement group_id="B3" value="50" lower_limit="30" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Three-year Relapse-free Survival</title>
        <description>Estimated using the product-limit method of Kaplan and Meier. Relapse defined as appearance of any new lesions during or after protocol treatment.</description>
        <time_frame>From date of mastectomy until date of relapse or death from any cause, 3 years post mastectomy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Chemo Followed by Surgery &amp; High-dose Chemo With PSC Rescue</title>
            <description>Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
cyclophosphamide&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
conventional surgery&#xD;
peripheral blood stem cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>High-dose Chemo With Rescue</title>
            <description>Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
peripheral blood stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Three-year Relapse-free Survival</title>
          <description>Estimated using the product-limit method of Kaplan and Meier. Relapse defined as appearance of any new lesions during or after protocol treatment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="30.8" upper_limit="81.8"/>
                    <measurement group_id="O2" value="77.8" lower_limit="57.1" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Five-year Overall Survival</title>
        <description>Estimated using the product-limit method of Kaplan and Meier. Endpoint is defined as death due to any cause.</description>
        <time_frame>From date of mastectomy until date of death, 5 years post mastectomy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Chemo Followed by Surgery &amp; High-dose Chemo With PSC Rescue</title>
            <description>Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
cyclophosphamide&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
conventional surgery&#xD;
peripheral blood stem cell transplantation</description>
          </group>
          <group group_id="O2">
            <title>High-dose Chemo With Rescue</title>
            <description>Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
peripheral blood stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Five-year Overall Survival</title>
          <description>Estimated using the product-limit method of Kaplan and Meier. Endpoint is defined as death due to any cause.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="37.3" upper_limit="87.2"/>
                    <measurement group_id="O2" value="70.4" lower_limit="49.4" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed during all cycles of chemotherapy treatment (up to 6 months).</time_frame>
      <desc>&quot;Other Adverse Events&quot; include all events that were not severe adverse events regardless of grade or relation to treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Neoadjuvant Chemo Followed by Surgery &amp; High-dose Chemo With PSC Rescue</title>
          <description>Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
cyclophosphamide&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
conventional surgery&#xD;
peripheral blood stem cell transplantation</description>
        </group>
        <group group_id="E2">
          <title>High-dose Chemo With Rescue</title>
          <description>Following surgery patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.&#xD;
filgrastim&#xD;
cisplatin&#xD;
doxorubicin hydrochloride&#xD;
melphalan&#xD;
mesna&#xD;
paclitaxel&#xD;
tamoxifen citrate&#xD;
bone marrow ablation with stem cell support&#xD;
peripheral blood stem cell transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>meddra10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Alkalosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>meddra9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Clinical Coagulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Dysrhythmias</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Ischemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Pericardial</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">EF/CHF</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Hearing</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Vision</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Constipation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="30" subjects_affected="18" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="25" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Diarrhea (Somlo COH)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Dysphagia, esophagitis, odynophagia (Somlo COH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Incontinence NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="34" subjects_affected="18" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Nausea (Somlo COH)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Stomatitis/phayngitis (Somlo COH)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="35" subjects_affected="19" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Vomiting (Somlo COH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Stomatitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="26" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Fever (no infection)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="21" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oedema NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Allergy</sub_title>
                <counts group_id="E1" events="24" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="26" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="27" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Infection, Bacterial (COH)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="COH">AGC</sub_title>
                <counts group_id="E1" events="20" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="25" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Alk Phos (Somlo COH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Amylase</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Bilirubin</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Bilirubin (Somlo COH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">HGB/HCT</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Neutrophils (ANC) (Somlo COH)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <counts group_id="E1" events="39" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" events="53" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Partial Thromboplastin Time</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Platelets</sub_title>
                <counts group_id="E1" events="20" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="25" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">Platelets (Somlo COH)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Prothrombin Time</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">SGOT (Somlo COH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">SGOT/SGT</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="Somlo">SGPT (Somlo COH)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">WBC</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Weight (Food Intake)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Hypercalcemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="22" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E2" events="43" subjects_affected="23" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E2" events="42" subjects_affected="22" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Hypoglycemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="22" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="37" subjects_affected="21" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Cerebellar</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Cortical/State of Consciousness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Motor Activity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Peripheral Nervous System Sensory</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hallucination NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Ideation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Mood</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Fluid Retention</sub_title>
                <counts group_id="E1" events="24" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="26" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="COH">Pulmonary</sub_title>
                <counts group_id="E1" events="24" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="26" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hiccough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Extensive Skin Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Local Skin Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="26" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" events="29" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="COH">Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Frankel, Ph.D.</name_or_title>
      <organization>City of Hope</organization>
      <phone>626-218-5265</phone>
      <email>pfrankel@coh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

